A. Federici

发表

Contemporary issues in the management of von Willebrand disease

C. Königs, A. Federici, A. James, 2016, Thrombosis and Haemostasis.

Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010

J. Oldenburg, A. Federici, N. Ewing, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

P. Mannucci, Christine A. Lee, J. Goudemand, 2004, Blood.

Von Willebrand Disease Type 2M “Vicenza” in Italian and German Patients: Identification of the First Candidate Mutation (G3864A; R1205H) in 8 Families

P. Mannucci, P. Mannucci, F. Rodeghiero, 2000, Thrombosis and Haemostasis.

Laboratory Screening for Abnormalities of Primary Hemostasis: What's Next?

A. Federici, A. Lecchi, R. Lombardi, 2001 .

How I treat the acquired von Willebrand syndrome.

A. Ganser, J. Rand, A. Federici, 2011, Blood.

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study

F. Rosendaal, P. Mannucci, A. Tosetto, 2022, Journal of thrombosis and haemostasis : JTH.

VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

J. Goudemand, J. Eikenboom, J. Batlle, 2013, Blood.

THROMBOSIS AND HEMOSTASIS VWF propeptide and ratios between VWF , VWF propeptide , and FVIII in the characterization of type 1 von Willebrand disease

J. Goudemand, J. Eikenboom, J. Batlle, 2013 .

Platelet morphological changes in 2 patients with von Willebrand disease type 3 caused by large homozygous deletions of the von Willebrand factor gene

P. Nurden, A. Federici, A. Nurden, 2009, Haematologica.

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study

J. Goudemand, S. Lethagen, J. Eikenboom, 2009, Journal of Thrombosis and Haemostasis.

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

J. Goudemand, S. Lethagen, J. Eikenboom, 2008, Blood.

Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)

J. Goudemand, S. Lethagen, J. Eikenboom, 2008, Journal of thrombosis and haemostasis : JTH.

A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3

R. Marschalek, J. Oldenburg, G. Castaman, 2007, Journal of thrombosis and haemostasis : JTH.

Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

J. Goudemand, C. Halldén, S. Lethagen, 2007, Blood.

Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD

J. Goudemand, S. Lethagen, J. Eikenboom, 2006, Journal of thrombosis and haemostasis : JTH.

Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study

A. Tosetto, S. Lethagen, J. Eikenboom, 2006, Journal of thrombosis and haemostasis : JTH.

Clinical diagnosis of von Willebrand disease

A. Federici, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.

V. De Stefano, A. Falanga, M. Marietta, 2019, Blood transfusion = Trasfusione del sangue.

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

P. Mannucci, C. Rothschild, A. Borel‐Derlon, 2007, Journal of thrombosis and haemostasis : JTH.

Third Åland islands conference on von Willebrand disease, 26–28 September 2012: meeting report

V. Jiménez‐Yuste, M. Morfini, M. Makris, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation and management of postpartum hemorrhage: consensus from an international expert panel

J. Herman, S. Hofer, P. Kouides, 2014, Transfusion.

Pathophysiology and General Management of Patients with Massive Blood Loss

A. Federici, D. Prati, 2018, HemaSphere.

Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.

P. Kamphuisen, B. Konkle, P. Kouides, 2009, American journal of obstetrics and gynecology.

Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel.

Christine A. Lee, P. Kamphuisen, P. Kouides, 2011, European journal of obstetrics, gynecology, and reproductive biology.

Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients

E. Clementi, M. Gismondo, D. Cattaneo, 2014, ClinicoEconomics and outcomes research : CEOR.

Treatment of acquired von Willebrand syndrome in childhood.

A. Federici, M. Callaghan, Trisha E. Wong, 2013, Blood.

Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Jesús Martín Sánchez, M. Beksac, H. Goldschmidt, 2018, Clinical lymphoma, myeloma & leukemia.

Pregnancy complications and obstetric care in women with inherited bleeding disorders

A. Federici, F. Peyvandi, I. Garagiola, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Patients With Type 3 Severe von Willebrand Disease Are Not Protected Against Atherosclerosis: Results From a Multicenter Study in 47 Patients

F. Rosendaal, J. Reiber, M. Morfini, 2004, Circulation.

Efficacy and safety evaluation of Fanhdi® , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.

V. Jiménez‐Yuste, A. Federici, M. Álvarez‐Román, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.

G. Castaman, A. Federici, E. Marchesini, 2018, Blood transfusion = Trasfusione del sangue.

Diagnosis and management of von Willebrand disease in Italy

G. Castaman, A. Federici, E. Oliovecchio, 2018 .

Current and emerging approaches for assessing von Willebrand disease in 2016

A. Federici, 2016, International journal of laboratory hematology.

Towards a more automatic and rapid laboratory diagnosis of von Willebrand disease.

A. Federici, 2016, Thrombosis research.

Classification and Clinical Aspects of Von Willebrand Disease

A. Federici, 2014 .

The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.

P. Mannucci, M. Morfini, P. Bucciarelli, 2014, Blood.

Clinical and laboratory diagnosis of VWD.

A. Federici, 2014, Hematology. American Society of Hematology. Education Program.

Current Management of Patients with Severe von Willebrand Disease Type 3: A 2012 Update

P. James, A. Federici, 2012, Acta Haematologica.

von Willebrand's disease: a report from a meeting in the Åland islands

M. Laffan, R. Montgomery, A. Federici, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Management of Inherited von Willebrand Disease in Italy: Results from the Retrospective Study on 1234 Patients

A. Iorio, P. Mannucci, M. Morfini, 2011, Seminars in thrombosis and hemostasis.

von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels

D. Hampshire, J. Goudemand, J. Eikenboom, 2010, Journal of thrombosis and haemostasis : JTH.

The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease

A. Federici, 2009, Expert opinion on drug safety.

Classification of inherited von Willebrand disease and implications in clinical practice.

A. Federici, 2009, Thrombosis research.

Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.

P. Mannucci, G. Castaman, A. Federici, 1998, Blood.

A Sensitive Ristocetin Co-factor Activity Assay with Recombinant Glycoprotein Ibα for the Diagnosis of Patients with Low Von Willebrand Factor Levels

P. Mannucci, J. Ware, A. Federici, 2022 .

An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees

S. Head, D. Salomon, T. Mondala, 2006, Journal of thrombosis and haemostasis : JTH.

Antibodies to von Willebrand factor in von Willebrand disease.

A. Federici, P. Mannucci, 1995, Advances in experimental medicine and biology.

Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes

P. Mannucci, A. Federici, Z. Ruggeri, 1982 .

Guidelines for the diagnosis and management of von Willebrand disease in Italy

P. Mannucci, G. Castaman, A. Federici, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of the PFA-100® System in the Diagnosis and Therapeutic Monitoring of Patients with von Willebrand Disease

P. Bucciarelli, A. Federici, M. Cattaneo, 1999, Thrombosis and Haemostasis.

Gene deletions correlate with the development of alloantibodies in von Willebrand disease.

A. Federici, P. Mannucci, J. Sadler, 1987, The Journal of clinical investigation.

Acquired von Willebrand Syndrome: Data from an International Registry

P. V. van Genderen, H. Mohri, P. Bucciarelli, 2000, Thrombosis and Haemostasis.

Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.

A. Federici, P. Mannucci, Z. Ruggeri, 1982, Blood.

Ristocetin Cofactor and Collagen Binding Activities Normalized to Antigen Levels for a Rapid Diagnosis of Type 2 von Willebrand Disease

A. Federici, M. Canciani, I. Forza, 2000, Thrombosis and Haemostasis.

Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.

A. Srivastava, P. Mannucci, A. Federici, 2003, Blood cells, molecules & diseases.

Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia

D. Consonni, A. Patriarca, M. Filocamo, 2021, Scientific Reports.

HDL/ApoA-I: role in VWF-dependent thrombosis.

A. Federici, 2016, Blood.

Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis

P. Bucciarelli, A. Cortelezzi, A. Federici, 2011, American journal of hematology.

Conformational Changes in the A1 Domain of von Willebrand Factor Modulating the Interaction with Platelet Glycoprotein Ib (*)

J. Ware, S. Miyata, A. Federici, 1996, The Journal of Biological Chemistry.

Faculty Opinions recommendation of The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

A. Federici, 2007 .

Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size

P. Mannucci, A. Federici, S. Pagani, 1989, British journal of haematology.

Pathophysiology, Epidemiology, Diagnosis, and Treatment of Acquired von Willebrand Syndrome

J. Rand, A. Federici, U. Budde, 2011 .

Acquired von Willebrand Syndrome Associated with Hypothyroidism: A Mild Bleeding Disorder to Be Further Investigated

A. Federici, Augusto Federici1, 2011, Seminars in thrombosis and hemostasis.

Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance

A. Tosetto, F. Rodeghiero, G. Castaman, 2011, Thrombosis and Haemostasis.

Evidence-based recommendations on the treatment of von Willebrand disease in Italy.

P. Mannucci, M. Franchini, G. Castaman, 2009, Blood transfusion = Trasfusione del sangue.

The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease.

A. Federici, 2009, Expert opinion on drug safety.

Prophylaxis of bleeding episodes in patients with von Willebrand's disease.

A. Federici, 2008, Blood transfusion = Trasfusione del sangue.

Management of inherited von Willebrand disease.

A. Federici, P. Mannucci, P. M. Mannucci, 2001, Best practice & research. Clinical haematology.

Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 Update

J. Rand, G. Castaman, A. Federici, 2013, Seminars in Thrombosis & Hemostasis.

Management of inherited von Willebrand disease in 2007

A. Federici, P. Mannuccio Mannucci, 2007, Annals of medicine.

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease

M. Morfini, M. Franchini, G. Barillari, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of highly purified, doubly virus‐inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score

G. Barillari, A. Federici, E. Zanon, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Secondary long-term prophylaxis in von Willebrand disease: an Italian cohort study

P. Mannucci, A. Federici, F. Gianniello, 2009 .

Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.

P. Mannucci, M. Morfini, M. Franchini, 2007, Haematologica.

Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys

A. Federici, 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Clinical efficacy of highly purified, doubly virus‐inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: a retrospective clinical study

A. Federici, M. Mazzucconi, P. Schinco, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas

C. Sabin, K. Friedman, G. Castaman, 2011, Journal of thrombosis and haemostasis : JTH.

von Willebrand disease in the 21st century: current approaches and new challenges

P. Mannucci, C. Kessler, A. Federici, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Acquired von Willebrand syndrome 2004: International Registry

J. Rand, A. Federici, U. Budde, 2004, Hämostaseologie.

Life‐threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor

P. Mannucci, D. Altieri, Francesco Saverio Tedesco, 1987, European journal of haematology.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

A. Tosetto, J. Goudemand, S. Lethagen, 2008, Blood.

Von Willebrand factor in high‐purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report

A. Federici, P. Mannucci, P. Marco, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM)

A. Tosetto, A. Falanga, M. Marietta, 2013 .

Increased von Willebrand factor antigen in the plasma of patients with vasculitis.

A. Federici, J. Curd, T. Zimmerman, 1984, Arthritis and rheumatism.

Hemostasis Testing during Massive Blood Replacement

G. Sirchia, A. Federici, P. Mannucci, 1982 .

Acquired von Willebrand syndrome type 2 A in a JAK 2-positive essential thrombocythaemia-affected member of a large von Willebrand disease family with a novel autosomal dominant A 1716 P mutation

A. Federici, P. Gresele, L. Baronciani, 2018 .

Acquired von Willebrand syndrome type 2A in a JAK2-positive essential thrombocythaemia -affected member of a large von Willebrand disease family with a novel autosomal dominant A1716P mutation

A. Federici, P. Gresele, L. Baronciani, 2011, Thrombosis and Haemostasis.

Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?

A. Federici, 2008, Journal of thrombosis and haemostasis : JTH.

State of the art: von Willebrand disease

J. Eikenboom, A. Federici, A. James, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders.

A. Federici, 2006, Seminars in hematology.

Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction.

P. Mannucci, S. Berkowitz, A. Federici, 1992, Blood.

The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease

P. Mannucci, C. Rothschild, F. Rodeghiero, 1994, British journal of haematology.

The 80th anniversary of von Willebrand's disease: history, management and research

A. Federici, E. Berntorp, C. Lee, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Type I von Willebrand disease, subtype ‘platelet low’: decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells

J. Sixma, P. Mannucci, M. Moia, 1993, British journal of haematology.

In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma.

J. Sixma, P. Mannucci, P. D. de Groot, 1992, Thrombosis research.

Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis.

P. Mannucci, S. Berkowitz, A. Federici, 1993, Blood.

An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets.

S. Mundell, S. Watson, A. Mumford, 2011, Blood.

Adhesive properties of the carbohydrate-modified von Willebrand factor (CHO-vWF).

J. Sixma, P. Mannucci, P. D. de Groot, 1988, Blood.

Impaired Platelet Function in a High Shear Stress System 1 Levels in Type I von Willebrand Disease Correlate With β Low Platelet ?2

A. Federici, M. Kritzik, T. Kunicki, 2013 .

Use of the von Willebrand factor concentrate with low factor VIII content to manage patients with inherited von Willebrand disease requiring surgical or secondary long‐term prophylaxis: An expert opinion paper from an Italian panel

G. Castaman, A. Federici, E. Marchesini, 2022, European journal of haematology.

Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients: a reply to a rebuttal

G. Castaman, A. Federici, L. Baronciani, 2012 .

von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M

P. Mannucci, A. Federici, A. Federici, 2006, Journal of thrombosis and haemostasis : JTH.

Type 2A (IIH) von Willebrand disease is due to mutations that affect von Willebrand factor multimerization

P. Mannucci, A. Federici, L. Baronciani, 2009, Journal of thrombosis and haemostasis : JTH.

A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.

A. Federici, C. Mazurier, L. Baronciani, 2004, Haematologica.

Duodenal and gastric Dieulafoy's lesions in a patient with type 2A von Willebrand's disease.

G. Costamagna, C. Spada, L. Petruzziello, 2005, Gastrointestinal endoscopy.

A new variant of type II von Willebrand disease with aberrant multimeric structure of plasma but not platelet von Willebrand factor (type IIF).

A. Federici, P. Mannucci, Z. Ruggeri, 1986, Blood.

Therapeutic approaches to acquired von Willebrand syndrome

A. Federici, 2000, Expert opinion on investigational drugs.

Studies of multimerin in patients with von Willebrand disease and platelet von Willebrand factor deficiency

Pille Harrison, P. Mannucci, A. Federici, 1998, British journal of haematology.

The factor VIII/von Willebrand factor complex: basic and clinical issues.

A. Federici, 2003, Haematologica.

von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets

P. Noris, A. Federici, C. Balduini, 2006, Platelets.

Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome

C. Kessler, J. Rand, A. Federici, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Transfusion issues in cancer patients.

A. Federici, C. Vanelli, L. Arrigoni, 2012, Thrombosis research.

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

P. Mannucci, J. Eikenboom, R. Montgomery, 2006, Journal of thrombosis and haemostasis : JTH.

Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry

C. Lodigiani, A. Falanga, C. Santoro, 2019, British journal of haematology.

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate®P/ Humate®‐P: History and clinical performance

P. Mannucci, G. Auerswald, M. Franchini, 2008, European journal of haematology. Supplementum.

Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality

G. Castaman, A. Federici, 2016, Seminars in Thrombosis & Hemostasis.

Prophylaxis in patients with von Willebrand disease: who, when, how?

A. Federici, 2015, Journal of thrombosis and haemostasis : JTH.

Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients

P. Mannucci, A. Tosetto, F. Rodeghiero, 2012, Journal of thrombosis and haemostasis : JTH.

Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.

P. Mannucci, P. D. de Groot, P. Lenting, 2009, Blood.

Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study

A. Federici, A. Federici, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD)

A. Tosetto, J. Goudemand, S. Lethagen, 2006, Journal of thrombosis and haemostasis : JTH.

The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study

A. Tosetto, S. Lethagen, J. Eikenboom, 2005, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods

P. Mannucci, A. Borel‐Derlon, J. Goudemand, 2005, Journal of thrombosis and haemostasis : JTH.

On the Use of Desmopressin in von Willebrand Disease

S. Lethagen, G. Castaman, A. Federici, 2011 .

Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors.

P. Mannucci, A. Federici, M. Cattaneo, 1979, Thrombosis research.

Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders.

J. Rand, A. Federici, P. Mannucci, 2001, The hematology journal : the official journal of the European Haematology Association.

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

A. Iorio, A. Bertomoro, V. Jiménez‐Yuste, 2019, Blood transfusion = Trasfusione del sangue.

A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000)

E. Sacchi, A. Federici, E. Rossi, 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Von Willebrand's disease: clinical management

A. Thompson, G. Castaman, A. Federici, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.

Francesco Rodeghiero, P. Mannucci, F. Rodeghiero, 2003, Haematologica.

Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network

P. Mannucci, L. Valentino, C. Kempton, 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Advances in the genetics and treatment of von Willebrand disease.

P. Mannucci, A. Federici, 2002, Current opinion in pediatrics.

An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient

U. Dianzani, G. Gaidano, R. Moia, 2020, Clinical case reports.

Fifth Åland Island conference on von Willebrand disease

M. Blombäck, P. T. Onundarson, P. Mannucci, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

von Willebrand Disease: a Report from a Meeting in the Åland Islands 2012 Summary of a Nordic Symposium on von Willebrand Disease, 26–28 September 2012, Mariehamn, Åland, Finland

V. Jiménez‐Yuste, M. Morfini, M. Makris, 2013 .

The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease

M. Makris, A. Federici, E. Berntorp, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease

J. Eikenboom, A. Federici, L. Baronciani, 2011 .

Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF?

A. Federici, 2008, Journal of thrombosis and haemostasis : JTH.

Diagnosis of von Willebrand disease

C. Kessler, A. Federici, U. Martinowitz, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H‐M740I) defect

F. Rodeghiero, G. Castaman, A. Federici, 2006, Journal of thrombosis and haemostasis : JTH.

Update on the management of von Willebrand disease.

A. Federici, 2008, Clinical advances in hematology & oncology : H&O.

Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.

A. Federici, P. Mannucci, R. Coppola, 1995, The Journal of laboratory and clinical medicine.

Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa

P. Mannucci, A. Federici, F. Pareti, 1990, British journal of haematology.

Diagnosis and management of von Willebrand disease

P. Mannucci, A. Federici, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Diagnosis of inherited von Willebrand disease: a clinical perspective.

A. Federici, 2006, Seminars in thrombosis and hemostasis.

Secondary Long-Term Prophylaxis in Severe Patients with von Willebrand’s Disease: An Italian Cohort Study.

P. Mannucci, A. Federici, M. Canciani, 2005 .

The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977–2007)

A. Federici, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Sixth Åland Island Conference on von Willebrand disease

J. Johnsen, A. Federici, E. Berntorp, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Von Willebrand Disease: Basic and Clinical Aspects

Christine A. Lee, R. Montgomery, A. Federici, 2011 .

The impact of bleeding history, von Willebrand factor and PFA–100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM‐1VWD

A. Tosetto, J. Goudemand, S. Lethagen, 2010, British journal of haematology.

Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study

P. Mannucci, J. Oldenburg, M. Morfini, 2020, Journal of thrombosis and haemostasis : JTH.

Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease

A. Federici, M. Canciani, 2009, Haematologica.

Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B.

P. Nurden, A. Federici, A. Nurden, 2010, Blood.

Altered megakaryocytopoiesis in von Willebrand type 2B disease

P. Nurden, A. Federici, A. Nurden, 2009, Journal of thrombosis and haemostasis : JTH.

Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD)

A. Tosetto, J. Goudemand, S. Lethagen, 2007, Journal of thrombosis and haemostasis : JTH.

Efficacy and safety evaluation of Fanhdi®, a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study

V. Jiménez‐Yuste, A. Federici, M. Álvarez‐Román, 2022 .

Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.

P. Mannucci, A. Tosetto, J. Goudemand, 2021, Blood advances.

Molecular Characterization of a Multiethnic Group of 21 Patients with Type 3 von Willebrand Disease

P. Mannucci, P. Mannucci, A. Federici, 2000, Thrombosis and Haemostasis.

A comparison between two semi‐quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease

A. Tosetto, J. Goudemand, S. Lethagen, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees.

J. Koziol, S. Head, D. Salomon, 2004, Blood.

Type II H von willebrand disease: New structural abnormality of plasma and platelet von willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity

P. Mannucci, A. Federici, R. Lombardi, 1989, American journal of hematology.

von Willebrand factor synthesized by endothelial cells from a patient with type IIB von Willebrand disease supports platelet adhesion normally but has an increased affinity for platelets.

J. Sixma, P. Mannucci, P. D. de Groot, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

G. Corrao, F. Gherlinzoni, P. Galieni, 2020, The Lancet Haematology.

Low Platelet 2β1 Levels in Type I von Willebrand Disease Correlate With Impaired Platelet Function in a High Shear Stress System

P. Mannucci, A. Federici, M. Kritzik, 1999 .

Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system.

P. Mannucci, J. Di Paola, A. Federici, 1999, Blood.

First report of reproductive assistance in a woman affected by May-Hegglin anomaly

I. Cetin, A. Federici, V. Savasi, 2012, Archives of Gynecology and Obstetrics.

YNECOLOGY on Willebrand disease and other bleeding isorders in women : Consensus on diagnosis and anagement from an international expert panel

P. Kamphuisen, B. Konkle, P. Kouides, 2022 .

Mild forms of von Willebrand disease: diagnosis and management.

A. Federici, 2003, Current hematology reports.

Conditions Influencing the Interaction of Asialo von Willebrand Factor with Human Platelets – The Effects of External Ionized Calcium Concentration and the Role of Arachidonate Pathway

P. Mannucci, A. Federici, J. Mustard, 1988, Thrombosis and Haemostasis.

Scientific Report of the Registry on Acquired von Willebrand Syndrome : Recommendations for Diagnosis and Management

H. Mohri, P. Bucciarelli, J. Rand, 2000 .

Premature termination codon mutations in the von Willebrand factor gene are associated with allele-specific and position-dependent mRNA decay

P. Mannucci, S. Duga, M. Platé, 2010, Haematologica.

Activation-independent platelet adhesion and aggregation under elevated shear stress.

A. Federici, Z. Ruggeri, J. Orje, 2005, Blood.

The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.

E. Santagostino, P. Mannucci, A. Federici, 2006, Haematologica.

Liver transplantation in severe von Willebrand disease

P. Mannucci, A. Federici, M. Cattaneo, 1991, The Lancet.

Autopsy Findings in Three Patients with von Willebrand Disease Type IIB and Type III: Presence of Atherosclerotic Lesions without Occlusive Arterial Thrombi

A. Federici, P. Mannucci, A. Federici, 1993, Thrombosis and Haemostasis.

A Type 2b von Willebrand Disease Mutation (lle546→Val) Associated with an Unusual Phenotype

P. Mannucci, J. Ware, S. Miyata, 1997, Thrombosis and Haemostasis.

Acute promyelocytic leukemia with unusual morphological features, absence of the t(15,17) and rearranged PML/RAR alpha genes.

P. Mannucci, A. Cortelezzi, A. Federici, 1994, Haematologica.

Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver

P. Mannucci, A. Federici, A. Federici, 1993 .

SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort

F. Gherlinzoni, B. Falini, L. Pagano, 2022, Hematological oncology.

Markers of vascular injury in Behçet's disease associated with retinal vasculitis.

R. Priori, G. Valesini, A. Federici, 1992, Annals of ophthalmology.

Profound alterations of the multimeric structure of von Willebrand factor in a patient with malignant lymphoma

P. Mannucci, A. Federici, P. Schneider, 1985, British journal of haematology.

Further characterization of platelet-type von Willebrand's disease in Japan

A. Federici, A. Federici, Z. Ruggeri, 1984 .

Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.

A. Federici, 2005, Human immunology.

An Additional Unique Candidate Mutation (G2470A; M740I) in the Original Families with von Willebrand Disease Type 2 M Vicenza and the G3864A (R1205H) Mutation

E. Missiaglia, F. Rodeghiero, G. Castaman, 2000, Thrombosis and Haemostasis.

Are intravenous immunoglobulins really inappropriate in acquired von Willebrand syndrome?

E. Sacchi, V. Rossi, M. Franchini, 2012, Blood transfusion = Trasfusione del sangue.

Willebrand Disease (VWD) type 1 pedigrees An association of candidate gene haplotypes and bleeding severity in Von

J. Koziol, D. Salomon, A. Federici, 2013 .

Von Willebrand Disease (vwd) Type 1 Pedigrees an Association of Candidate Gene Haplotypes and Bleeding Severity In

J. Koziol, S. Head, D. Salomon, 2022 .

Diagnosis and management of acquired von Willebrand syndrome.

P. Mannucci, A. Federici, 2003, Clinical advances in hematology & oncology : H&O.

Abnormal Large Platelets Are Associated Not Only with von Willebrand Disease (VWD) Type 2B (Including Type 2B/1 New York) but Also with Severe Type 3: A Potential Role for von Willebrand Factor (VWF) in Megakaryocytopoiesis.

P. Nurden, A. Federici, A. Nurden, 2007 .

Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding

A. Federici, L. Baronciani, M. Canciani, 2005, Journal of thrombosis and haemostasis : JTH.

CLINICAL AND MOLECULAR PREDICTORS OF THROMBOCYTOPENIA AND RISK OF BLEEDING IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 2B: A COHORT STUDY OF 67 PATIENTS Running title: Thrombocytopenia and bleeding risk in VWD 2B

P. Mannucci, P. Lenting, P. Bucciarelli, 2008 .

Impaired megakaryocytopoiesis in type 2B von Willebrand disease

A. Federici, 2006 .

Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF)

P. Mannucci, A. Federici, R. De Cristofaro, 2006, Journal of Biological Chemistry.

Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease.

A. Tosetto, A. Federici, M. Canciani, 2007, Haematologica.

Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.

A. Tosetto, J. Goudemand, S. Lethagen, 2010, Thrombosis research.

Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all‐trans‐retinoic acid

T. Barbui, P. Mannucci, A. Falanga, 1996, British journal of haematology.

A need to increase von Willebrand disease awareness: vwdtest.com - A global initiative to help address this gap.

A. Federici, A. Dougall, E. Berntorp, 2022, Blood reviews.

Antiendothelial cell antibodies in primary vasculitides.

A. Tincani, P. Meroni, A. Federici, 1991, Contributions to Nephrology.

Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease.

F. Pecori Giraldi, A. Ambrogio, F. Cavagnini, 2011, British journal of clinical pharmacology.

human platelets purinoceptor traffic in 12 An intact PDZ motif is essential for correct P2Y

S. Mundell, A. Mumford, A. Federici, 2012 .

elevated shear stress Activation-independent platelet adhesion and aggregation under

A. Federici, Z. Ruggeri, J. Orje, 2013 .

Supportive transfusion therapy in cancer patients with acquired defects of hemostasis.

E. Sacchi, D. Intini, A. Federici, 2014, Thrombosis research.

Coagulation factor XIII, endothelial damage and systemic sclerosis.

A. Federici, P. Mannucci, A. Marzano, 2000, European journal of dermatology : EJD.

European Study MCMDM-1VWD phenotype in type 1 von Willebrand disease (VWD): results from the Response to desmopressin is influenced by the genotype and

A. Tosetto, J. Goudemand, S. Lethagen, 2013 .

Von Willebrand disease: Gaining a global perspective.

J. Stonebraker, M. Makris, P. James, 2023, Haemophilia : the official journal of the World Federation of Hemophilia.

Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from von Willebrand disease type 2B patients Short Title: Abnormal platelet production in human VWD2B

P. Nurden, M. Vitale, A. Federici, 2010 .

Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.

P. Mannucci, M. Morfini, P. Bucciarelli, 2007 .

Diagnosis and classification of von Willebrand disease

A. Bianchi, Regina Elena, A. Federici, 2007 .

Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients

A. Federici, F. Peyvandi, R. Asselta, 2012, American journal of hematology.

Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party.

V. De Stefano, A. Falanga, G. Castaman, 2016, Blood transfusion = Trasfusione del sangue.

Acute promyelocytic leukemia with unusual morphological features, absence of the t(15,17) and rearranged PML/RAR alpha genes.

P. Mannucci, A. Cortelezzi, A. Federici, 1994, Haematologica.

Platelet Adhesion to Collagen in Subtypes of Type I von Willebrand’s Disease Is Dependent on Platelet von Willebrand Factor

J. Sixma, G. Mariani, J. Zwaginga, 1990, Thrombosis and Haemostasis.

Role for platelet von willebrand factor in supporting platelet‐vessel wall interactions in von willebrand disease

P. Mannucci, M. Moia, G. Escolar, 1989, American journal of hematology.

Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.

G. Mariani, P. Mannucci, A. Federici, 1985, Blood.

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

P. Mannucci, Christine A. Lee, J. Goudemand, 2004, Blood.

Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

A. Federici, A. Federici, Z. Ruggeri, 1984, The Journal of clinical investigation.

Clinical Observations, Interventions, and Therapeutic Trials

P. Mannucci, Christine A. Lee, J. Goudemand, 2000 .

Laboratory issues in bleeding disorders

F. Rodeghiero, A. Federici, D. Lillicrap, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients

A. Iorio, G. Castaman, A. Federici, 2010 .

Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease: Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group

A. Federici, E. Berntorp, T. Abshire, 2010 .

Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial

J. Goedert, J. Goedert, L. Preiss, 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

Von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly- Asp-dependent mechanism

M. Lampugnani, E. Dejana, P. Marchisio, 1989, The Journal of cell biology.

Studies with the Nanobody That Detects the Gain-of-Function of von Willebrand Factor in a Cohort of Patients with Type 2B von Willebrand Disease: Correlation with Platelet Count, VWF Multimers and Molecular Defects.

P. Mannucci, P. Lenting, A. Federici, 2006 .

How I treat the acquired von Willebrand syndrome